FEMASYS INC. - COMMON

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

03 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

27 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

25 Sep 2023 17:25:04 By Nasdaq GlobeNewswire

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

20 Sep 2023 08:30:09 By Nasdaq GlobeNewswire

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

31 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

10 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

03 Aug 2023 08:45:00 By Nasdaq GlobeNewswire

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

27 Jul 2023 08:45:00 By Nasdaq GlobeNewswire

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

26 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

15 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

14 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

08 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting

11 May 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

03 May 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology

01 May 2023 16:05:00 By Nasdaq GlobeNewswire

Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

19 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire